The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
LNA-modified oligonucleotides mediate specific inhibition of microRNA function
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
RAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656
A microRNA polycistron as a potential human oncogene
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., et al. (2005) · Nature · doi:10.1038/nature03552 · Cited by 3,483
Cited by
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Endogenous microRNA sponges: evidence and controversy
Thomson, D. W., & Dinger, M. E. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.20 · Cited by 2,185
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
MicroRNAs in Cancer: Small Molecules With a Huge Impact
Iorio, M. V., & Croce, C. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0317 · Cited by 959
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
MicroRNA expression and function in cancer
Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A., & Croce, C. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.006 · Cited by 780
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
“There are three general methods for miRNA lossof-function studies: genetic knockouts, antisense oligonucleotide inhibitors (Meister et al. 2004; Krützfeldt et al. 2005; Ørom et al. 2006) and sponges (Ebert et al.”
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
Self-citationCeppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A., & Pierre, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811073106 · Cited by 631
Transcripts Targeted by the MicroRNA-16 Family Cooperatively Regulate Cell Cycle Progression
Linsley, P. S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M. M., Bartz, S. R., Johnson, J. M., Cummins, J. M., Raymond, C. K., Dai, H., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02005-06 · Cited by 552
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Practical Aspects of microRNA Target Prediction
M. Witkos, T., Koscianska, E., & J. Krzyzosiak, W. (2011) · Current Molecular Medicine · doi:10.2174/156652411794859250 · Cited by 466
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Corsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
MicroRNAs in Disease and Potential Therapeutic Applications
Soifer, H. S., Rossi, J. J., & Sætrom, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300311 · Cited by 394
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Broderick, J. A., & Zamore, P. D. (2011) · Gene Therapy · doi:10.1038/gt.2011.50 · Cited by 388
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths
Sayed, D., Rane, S., Lypowy, J., He, M., Chen, I.-Y., Vashistha, H., Yan, L., Malhotra, A., Vatner, D., & Abdellatif, M. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0159 · Cited by 355
“, 2004) or LNA-modified oligoribonuleotides (Orom et al., 2006), and ‘antagomirs’, which have a phosphorothioate backbone, a cholesterol-moiety at 3'-end, and 2'-Omethyl modifications (Krutzfeldt et al.”
BackgroundWang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 343
The role of microRNAs in cancer: No small matter
Wiemer, E. A. C. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.002 · Cited by 342
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
Ding, L., Xu, Y., Zhang, W., Deng, Y., Si, M., Du, Y., Yao, H., Liu, X., Ke, Y., Si, J., et al. (2010) · Cell Research · doi:10.1038/cr.2010.79 · Cited by 341
Causes and Consequences of MicroRNA Dysregulation
Iorio, M. V., & Croce, C. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318250c001 · Cited by 333
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Stittrich, A.-B., Haftmann, C., Sgouroudis, E., Kühl, A. A., Hegazy, A. N., Panse, I., Riedel, R., Flossdorf, M., Dong, J., Fuhrmann, F., et al. (2010) · Nature Immunology · doi:10.1038/ni.1945 · Cited by 314
Haraguchi, T., Ozaki, Y., & Iba, H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp040 · Cited by 305
“There are some available techniques designed to inhibit miRNA function, including the introduction of short, single-stranded oligonucleotides that are chemically modified such as 20-O-methyl (20-OMe) RNA (7,8), locked nucleic acid (LNA) molecules and ‘antagomirs’ ( 9 ,10).”
MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development
Boutz, P. L., Chawla, G., Stoilov, P., & Black, D. L. (2007) · Genes & Development · doi:10.1101/gad.1500707 · Cited by 304
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
Self-citationMicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment
Quiat, D., & Olson, E. N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62876 · Cited by 300
New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles
Zaimy, M. A., Saffarzadeh, N., Mohammadi, A., Pourghadamyari, H., Izadi, P., Sarli, A., Moghaddam, L. K., Paschepari, S. R., Azizi, H., Torkamandi, S., et al. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.16 · Cited by 289
Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)
Kaur, H., Babu, B. R., & Maiti, S. (2007) · Chemical Reviews · doi:10.1021/cr050266u · Cited by 285
Anti-miRNA oligonucleotides: A comprehensive guide for design
Lima, J. F., Cerqueira, L., Figueiredo, C., Oliveira, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 276
A microRNA component of the hypoxic response
Kulshreshtha, R., Davuluri, R. V., Calin, G. A., & Ivan, M. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402310 · Cited by 272
Inhibition of microRNA with antisense oligonucleotides
Esau, C. C. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 257
Fabani, M. M., & Gait, M. J. (2008) · RNA · doi:10.1261/rna.844108 · Cited by 252
Shibata, M., Kurokawa, D., Nakao, H., Ohmura, T., & Aizawa, S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3219-08.2008 · Cited by 210
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy
Iranifar, E., Seresht, B. M., Momeni, F., Fadaei, E., Mehr, M. H., Ebrahimi, Z., Rahmati, M., Kharazinejad, E., & Mirzaei, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27214 · Cited by 93
Nedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Nabinejad, A., Ferns, G. A., Ghayour-Mobarhan, M., & Salehi, R. (2017) · Tumor Biology · doi:10.1177/1010428317692261 · Cited by 47
Oh, S. Y., Ju, Y., Kim, S., & Park, H. (2010) · Oligonucleotides · doi:10.1089/oli.2010.0238 · Cited by 33
MicroRNAs as Regulators of Phagocytosis
Gierlikowski, W., & Gierlikowska, B. (2022) · Cells · doi:10.3390/cells11091380 · Cited by 25
Metadata
- Authors
- Ørom, U. A., Kauppinen, S., & Lund, A. H.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 372
- Pages
- 137-141
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2020326055
- Cited by
- 373
- References
- 31
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.